Active	Status	Sponsor type	Region	Phase	Filter
6 Active 0 Inactive 6 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

6 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Yuan, Jianlin
innovaTV 301, NCT04697628 / 2019-001655-39: Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer	Active, not recruiting	3	502	Europe, Canada, Japan, US, RoW	tisotumab vedotin, TIVDAK, topotecan, vinorelbine, gemcitabine, irinotecan, pemetrexed	Seagen Inc., Genmab	Cervical Cancer	07/23	08/25
TQB2450-II-08, NCT04574284: A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Subjects With Advanced Endometrial Cancer	Recruiting	2	196	RoW	TQB2450, Anlotinib	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Advanced Endometrial Cancer	12/21	04/22
NCT06014190: HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer	Recruiting	2	460	RoW	HS-20089	Hansoh BioMedical R&D Company	Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Endometrial Cancer	12/25	12/27
NCT05856929: Sexual Dysfunction After Renal Transplantation	Recruiting	N/A	500	RoW	no Intervention	Xijing Hospital	Sexual Dysfunction	01/24	06/24
NCT06677814: Development and Validation of an Anxiety Disorder Prediction Model for Premature Ejaculation Patients	Recruiting	N/A	700	RoW		Xijing Hospital	Premature Ejaculation, Anxiety	03/25	05/26
Kuerban, Gulina
TQB2450-II-08, NCT04574284: A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Subjects With Advanced Endometrial Cancer	Recruiting	2	196	RoW	TQB2450, Anlotinib	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Advanced Endometrial Cancer	12/21	04/22